Monica Scharfenort

Monica Scharfenort


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in European Journal of Neurology
Verified
Journal Article
Open access
MÖMezin Öthman
Mezin Öthman
Filip BergquistFilip Bergquist
Filip Bergquist
POPer Odin
Per Odin
MSMonica Scharfenort
Monica Scharfenort
AJAnders Johansson
Anders Johansson
Dag NyholmDag Nyholm
Dag Nyholm
Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long‐term efficacy and safety data are lacking.Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden.Methods: Real‐world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022.Results: A total of 150 patients were identified. Sixty‐one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device‐assisted therapy, mostly LCIG (39 patients).Reported complications were mainly related to PEG‐J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG.The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p‐Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ‐8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41).Conclusions: Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device‐aided therapy for advanced PD. However, the long‐term efficacy and tolerability of LECIG need to be further investigated.

5 May 2021 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
MSMonica Scharfenort
Monica Scharfenort
JTJonathan Timpka
Jonathan Timpka
TSThomas Sahlström
Thomas Sahlström
THTove Henriksen
Tove Henriksen
Dag NyholmDag Nyholm
Dag Nyholm
POPer Odin
Per Odin
Objectives: Deep brain stimulation, continuous subcutaneous apomorphine infusion, and levodopa–carbidopa intestinal gel infusion, together called device‐aided therapies (DAT), are introduced when oral and transdermal pharmacotherapy are not enough for a satisfactory control of Parkinson's disease (PD) symptoms. Solid relationships are central to an individual's well‐being, but the impact of close relationships in advanced PD remains underexplored. The aim of this study was to investigate the development of close relationships between PD patients and their partners following the initiation of DAT and to examine the relationship structures in these relationships.Materials and Methods: This was a retrospective quantitative multicenter pilot study wherein 41 couples, patients with advanced PD and their partners, retrospectively rated their relationship satisfaction before the start of DAT, after one year of DAT and at the time of the interview. The couples also answered the Experiences in Close Relationships—Questionnaire of Relational Structures (ECR‐RS).Results: Partners more often report changes in relationship satisfaction than patients between baseline and both 1 year after start of DAT (p = .049) and last evaluation (p = .041). The ECR‐RS data reported significantly higher avoidance score for partners (p = .005) and significantly higher anxiety score for patients (p = .024).Conclusions: The close relationship wherein one part has PD and receives DAT has a high risk of being unequal. Prospective studies are needed for further clarification of the interplay between advanced PD, DAT, and close relationships, this in order to improve pre‐ and postinterventional support for PD patients receiving DAT, as well as their partners.

1 January 2025 in Parkinson's Disease
Verified
Journal Article
Open access
MSMonica Scharfenort
Monica Scharfenort
VHVeronica Hernström
Veronica Hernström
KRKristina Rosqvist
Kristina Rosqvist
HLHanna Ljung
Hanna Ljung
MNMaria H Nilsson
Maria H Nilsson
POPer Odin
Per Odin
Background: It is unclear whether the two device‐aided therapies (DATs: deep brain stimulation [DBS] and levodopa–carbidopa intestinal gel [LCIG]) affect personality in patients with Parkinson’s disease (PD). Objective: This retrospective study aims to explore if patients with PD and their close relatives experience any changes in the patient’s personality following the start of DAT. Methods: In total, 32 patients with DAT (17 DBS and 15 levodopa pump–based therapy) and their close relatives ( n = 32) were asked to retrospectively assess potential personality changes in the patients using the Big Five Inventory (BFI) following DAT. They also answered questions regarding perceived quality of life and perceived impact on motor symptoms. Results: There was a diverse perceived change in the patients’ five personality traits when divided into the type of therapy. DBS patients reported decreased extraversion (70.6%, n = 12), while their close relatives reported an increase in the trait neuroticism (82.4%, n = 14). A significant difference was found in perceived changes in agreeableness, with 8 DBS patients reporting an increase and 4 close relatives reporting a decrease ( p = 0.008). Most of the pump patients (LCIG) reported a decreased conscientiousness (66.7% n = 10), a perception confirmed by 73.3% ( n = 11) of their close relatives, who in addition reported an increase in neuroticism (73.3%, n = 11). Conclusions: This study suggests perceived personality changes following DAT (DBS or LCIG), which vary by therapy and respondent role. Larger studies are needed, but the findings signal the importance of considering both patients’ and their relatives’ perspectives when assessing personality changes.

20 October 2026 in BMC Nursing
Verified
Journal Article
Open access
PDF file
MSMonica Scharfenort
Monica Scharfenort
ANAnette Nobrell
Anette Nobrell
MGMichela Garon
Michela Garon
KRKristina Rosqvist
Kristina Rosqvist
GPGesine Paul
Gesine Paul
EMElisabeth Mangrio
Elisabeth Mangrio
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting motor and non-motor functions. When oral medication no longer provides adequate control, device-aided therapies (DAT), including levodopa infusion therapy, may be introduced. Although DAT can improve symptom management, little is known about how people with PD (PwPD) and family caregivers (FC) experience the initiation process. This study explored PwPD and their FC perceptions during decision-making, therapy initiation, and subsequent adaptation to levodopa pump therapy. Methods: This qualitative study employed semi-structured interviews (6–24 months after treatment initiation) and latent reflexive thematic analysis with ten PwPD and nine FC recruited from two Swedish university hospitals. Results: Thematic analysis revealed four shared themes: (1) Living with the constraints of PD, (2) Sustaining hope in the face of therapeutic uncertainty, (3) Adapting to a new treatment while facing practical challenges, and (4) Relying on expertise while managing its absence. Pump therapy was often chosen due to limited alternatives and strong trust in the specialized multidisciplinary PD team. While both groups experienced symptom improvements, PwPD focused on autonomy whereas FC focused on responsibilities. Expectations were generally met, yet FC frequently felt underinformed about the realities of daily pump management. Conclusions: Our findings highlight that although symptom control improved, both PwPD and FC continued to face practical and emotional challenges. Supporting their adaptation process requires coordinated, person-centred preparation, guidance and follow-up from multidisciplinary, specialized PD teams. Clinical trial registration: Not applicable.